Background: Treatment of cutaneous leishmania-
INTRODUCTION
Leishmaniasis (cutaneous, mucocutaneous and visceral) is caused by parasites of the genus Leishmania, which are transmitted via sandfly bites. Cutaneous leishmaniasis is a major health problem in many parts of the world including Islamic Republic of Iran. 1 Despite ongoing research, safe and effective treatment is a challenge.
Pentavalent antimony derivatives are the first-line treatment modalities with a general cure rate of 60-80%, 2 although most of the trials are flawed by lack of clear and uniform outcome definitions, inappropriate design, inadequate sample size or follow-up. 3 Moreover, adverse effects are a major concern. Among the alternative treatments, physical modalities are of special interest. Cryotherapy, thermotherapy, photodynamic therapy and trichloroacetic acid peeling have been employed alone or in combination with antimoniates in a few clinical trials, most of which are either inadequately powered or inappropriately designed. 3 More recently, some laser systems have also been trialled including CO 2 laser (both fractional and traditional), but to our knowledge the efficacy of non-ablative fractional erbium glass laser has not been studied in cutaneous leishmaniasis.
The 1540-nm Fractional Erbium glass laser is an infrared photothermolysis device. It generates vertical microcolumns of thermal injury in the subepidermal area of skin which is followed by wound-healing. As the epidermis is not damaged, it needs less post-procedural care and there is a lower risk of adverse effects like secondary bacterial infection and post inflammatory dyspigmentation, making this technique more acceptable to the patient. 5, 6 This modality has been studied with variable success in the treatment of melasma, striae distensae, rhytides and different types of scars. Clinical and demographic data for each patient were recorded before the first treatment, and at the start of each treatment session; the size of lesions was recorded and digital photography was performed (power shot G12, Canon Inc, Ota, Tokyo, Japan).
Treatment protocol
Lesions were treated weekly with erbuim glass laser 1540 (Palomar Medical Technologies, Burlington, MA, USA). We used 10 mm spot size hand piece with 10-ms pulse duration and 40-70 J/cm 2 fluence in four passes (two perpendicular and two oblique) for each lesion, including a surrounding margin of 1 cm. If the lesions did not improve in four consecutive sessions, or worsened in three consecutive sessions, the treatment was ended and an alternative treatment was offered.
Outcome assessment
The primary outcome was percentage of completely healed non-ulcerated lesions at 3, 6 and 12 months after end of the treatment.
3,10
Reduction of induration in millimetres was measured by a calliper (Mini calliper, Vernier software and technology, Beaverton, Oregon, USA).
RESULTS
Fourteen patients (10 female), mean age 25.9 AE 14.7 years, with 20 lesions, were enrolled; Table 1 shows demographic, clinical characteristics and treatment results for the intended patients and lesions.
Four cases withdrew prematurely, and one patient had insufficient response so received standard treatment. Two children (cases No. 11 and 14) did not continue treatment because of pain; however case no 11 had healed by 2 months without further therapy but case no 14 received 10 weekly intralesional injections of meglumine antimoniate (Glucantime, Sanofi-Aventis, France).
Cases no 12 and 13 were lost to follow up after only a few treatment sessions.
Case no 10, a 16-year-old girl, had partial improvement of a lesion on her left leg, went on to receive systemic meglumine antimoniate (20 days of injections), as it was still indurated and ulcerated after nine treatment sessions. She was cured after 20 injections of meglumine antimoniate.
Nine patients with 12 lesions completed the treatment protocol. At the 6 week review, six out of 12 lesions improved completely (more than 90% reduction in lesion size and induration), and after 12 weeks, 11 lesions were completely healed. There were no recurrences at 6-and 12-month follow-ups. No adverse effects except for temporary erythema and oedema (for 2-5 days) and pain during the procedure were reported. Figures 1 and 2 show the improvement in two cases of cutaneous leishmaniasis after laser treatment sessions.
DISCUSSION
The results of this case series are suggestive of the applicability of 1540 erbium glass laser in the treatment of Old World cutaneous leishmaniasis.
Ablative lasers like CO 2 have an established place in the treatment of Old World cutaneous leishmaniasis scars, which is most commonly a shallow atrophic scar. [11] [12] [13] [14] Although in vitro studies have showed that He:Ne and NdYag lasers affect the viability of Leishmania major and L. donovanni promastigotes in culture media, 15, 16 clinical application of these lasers has not been reported. 
Successful application of thermotherapy measures to induce healing in cutaneous leishmaniasis lesions led to the idea that selectiveness in heat therapy may increase the efficacy and decrease the risk of unwanted side effects. 17 Moreover, efficacy of fractional laser skin resurfacing in the treatment of chronic wounds, possibly through modulations in wound field environment and growth factors, triggered the idea of their potential usefulness in the treatment of cutaneous leishmaniasis. 18 Only recently, a limited number of clinical trials with Argon and CO 2 and PDL lasers in the treatment of cutaneous leishmaniasis have been published. [19] [20] [21] [22] [23] Asilian et al. 24 compared CO 2 fractional with systemic antimoniate in the treatment of cutaneous leishmaniasis and reported greater efficacy, shorter healing time and fewer side effects and more cost-effectiveness of the former treatment method. Seven of 111 lesions treated with fractional CO 2 laser recurred at 1 month. In another study, a treatment resistant ulcer due to cutaneous leishmaniasis was treated successfully with a single session of CO 2 fractional laser followed by daily application of topical paromomycin for 1 month. 25 Lasers may also be helpful in the treatment of chronic (lupoid) cutaneous leishmaniasis, which is scarring and resistant to standard treatments. In a case series of 24 patients with chronic cutaneous leishmaniasis longer than 1 year duration. 19 cases were cured after a single session of CO 2 fractional laser with no recurrence at 1-year followup. 26 The applicability of other fractional laser system in this field and comparison to other treatment modalities has yet to be determined.
The major limitation of the current study is limited number of lesions and lack of a control group. Bearing in mind the self-healing course of cutaneous leishmaniasis in many cases, the need for a control group seems imperative. Erbium glass laser and cutaneous leishmaniasis e31
